Published in J Infect Dis on June 01, 1995
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev (2008) 2.88
Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother (1996) 1.65
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob Agents Chemother (2001) 1.32
Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother (1999) 1.25
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother (2004) 1.19
Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother (1998) 1.16
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Rev (2000) 1.15
Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br J Clin Pharmacol (1998) 1.08
Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother (2003) 0.99
A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides. J Virol (1997) 0.95
A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother (2000) 0.90
The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells. Br J Clin Pharmacol (2000) 0.89
L-ATP is recognized by some cellular and viral enzymes: does chance drive enzymic enantioselectivity? Biochem J (1999) 0.82
Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure. Br J Clin Pharmacol (2007) 0.80
Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine. Antimicrob Agents Chemother (1997) 0.80
In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother (1996) 0.79
The renaissance of fixed dose combinations: Combivir. Ther Clin Risk Manag (2007) 0.78
Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother (2002) 0.75
The pharmacokinetics of lamivudine in healthy Chinese subjects. Br J Clin Pharmacol (1999) 0.75
Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS (1997) 9.08
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA (2001) 7.63
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA (1998) 6.69
Barriers to use of free antiretroviral therapy in injection drug users. JAMA (1998) 6.67
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ (2001) 4.96
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Adverse reactions during hospitalization. Can Med Assoc J (1967) 3.96
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med (1995) 3.86
HIV-1 and the aetiology of AIDS. Lancet (1993) 3.69
Prevalence and structural correlates of gender based violence among a prospective cohort of female sex workers. BMJ (2009) 3.56
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ (1999) 3.35
Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS (1989) 3.19
Decline in deaths from AIDS due to new antiretrovirals. Lancet (1997) 3.13
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med (1997) 3.03
Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr (2000) 2.94
Comparative bioavailability of three brands of ampicillin. Can Med Assoc J (1972) 2.87
Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS) Ann Intern Med (1990) 2.85
A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk. AIDS (2000) 2.71
Lower socioeconomic status and shorter survival following HIV infection. Lancet (1994) 2.47
Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet (2000) 2.42
The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis (1998) 2.31
Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genitourin Med (1995) 2.22
Decreasing frequency but worsening mortality of acute respiratory failure secondary to AIDS-related Pneumocystis carinii pneumonia. Chest (1994) 2.10
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03
Adverse drug reactions during hospitalization. Can Med Assoc J (1967) 2.01
An educational program in digitalis therapy. JAMA (1972) 1.99
Determinants of sexual risk-taking among young HIV-negative gay and bisexual men. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.99
Methyl mercury exposure in northern Quebec. II. Neurologic findings in children. Am J Epidemiol (1983) 1.88
Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS (1999) 1.87
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS (1999) 1.85
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS (1998) 1.81
Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS (1989) 1.78
Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med (1988) 1.77
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS (2001) 1.73
Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.68
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis (2001) 1.62
Undergraduate and postgraduate medical education in Canada. CMAJ (1998) 1.61
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS (1995) 1.58
Severe lithium intoxication: management without dialysis and report of a possible teratogenic effect of lithium. Can Med Assoc J (1971) 1.54
Evidence for a sexually transmitted cofactor for AIDS-related Kaposi's sarcoma in a cohort of homosexual men. Epidemiology (1992) 1.53
Antiretroviral medication use among injection drug users: two potential futures. AIDS (2000) 1.53
Pharmacokinetics of amoxicillin. Clin Pharmacol Ther (1974) 1.45
Depressive symptoms decline among persons on HIV protease inhibitors. J Acquir Immune Defic Syndr (2000) 1.42
Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. Canadian HIV Trials Network A002 Study Group. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.39
Influence of zidovudine on progression to AIDS in cohort studies. Lancet (1989) 1.38
Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS (1993) 1.36
Clinical skills of medical residents: a review of physical examination. CMAJ (1988) 1.29
Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS (2001) 1.22
The effect of cigarette smoking on lymphocyte subsets and progression to AIDS in a cohort of homosexual men. Clin Invest Med (1992) 1.20
Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother (2001) 1.20
Variation in plasma RNA levels, CD4 cell counts, and p24 antigen levels in clinically stable men with human immunodeficiency virus infection. J Infect Dis (1996) 1.18
Strong and macroporous calcium phosphate cement: Effects of porosity and fiber reinforcement on mechanical properties. J Biomed Mater Res (2001) 1.17
Modelling the impact of HIV disease on mortality in gay and bisexual men. Int J Epidemiol (1997) 1.17
Wear and mechanical properties of nano-silica-fused whisker composites. J Dent Res (2004) 1.17
Methyl mercury exposure in northern Quebec. I. Neurologic findings in adults. Am J Epidemiol (1983) 1.17
Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms. HIV Med (2003) 1.15
Spectrum of tuberculosis in patients with HIV infection in British Columbia: report of 40 cases. CMAJ (1992) 1.15
Practical concepts of drug absorption, distribution and loss. Can Med Assoc J (1974) 1.15
pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother (1993) 1.14
Antihypertensive and biochemical effects of chlorthalidone. Clin Pharmacol Ther (1977) 1.11
Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS (2000) 1.11
HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort. AIDS (2001) 1.10
Rebound of plasma HIV viral load following prolonged suppression with combination therapy. AIDS (1998) 1.09
The effects of peritoneal dialysis on the physiological disposition of oxacillin, ampicillin and tetracycline in patients with renal disease. Can Med Assoc J (1966) 1.09
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS (2001) 1.07
Sociodemographic correlates for risk-taking behaviour among HIV seronegative homosexual men. Can J Public Health (1994) 1.07
Determinants of hospital admission among HIV-positive people in British Columbia. CMAJ (2000) 1.07
Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol (1999) 1.07
Bitter pill: the current state of antiretroviral care in selected nations around the globe. AIDS (1999) 1.06
Treatment of benign prostatic hypertrophy with medrogestone. Clin Pharmacol Ther (1971) 1.06
A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J Infect Dis (1998) 1.06
Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI). Ann Intern Med (1991) 1.05
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials. Antimicrob Agents Chemother (1992) 1.05
Processing and properties of strong and non-rigid calcium phosphate cement. J Dent Res (2002) 1.05
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS (1999) 1.04
Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.01
Surgical management of pneumothorax in patients with acquired immunodeficiency syndrome. Arch Surg (1991) 1.01
The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS (1998) 1.01
Alveolar epithelial damage. A critical difference between high pressure and oleic acid-induced low pressure pulmonary edema. J Clin Invest (1986) 0.99
Vertically transmitted babesiosis. J Pediatr (1997) 0.99
Methylmercury poisoning. CMAJ (2001) 0.98
Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men. AIDS (1989) 0.97
On the brittleness of enamel and selected dental materials. Dent Mater (2008) 0.97
Canadian multicenter azidothymidine trial: AZT pharmacokinetics. J Acquir Immune Defic Syndr (1991) 0.96
A comparison of the analgesic efficacy of naproxen and acetylsalicylic acid-codeine in patients with pain after dental surgery. Scand J Rheumatol Suppl (1973) 0.96
A comparison of the analgesic efficacy of naproxen and propoxyphene in patients with pain after orthopedic surgery. Scand J Rheumatol Suppl (1973) 0.94
Determinants of short- and long-term outcome in patients with respiratory failure caused by AIDS-related Pneumocystis carinii pneumonia. Arch Intern Med (1999) 0.94